<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>1 </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of this study was to evaluate the broad neurocytoprotective potential of the novel <z:chebi fb="199" ids="26708">sodium</z:chebi>-<z:chebi fb="0" ids="39124">calcium ion</z:chebi> channel modulator, lifarizine (RS-87476), in two rodent 72 h survival models of forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>2 </plain></SENT>
<SENT sid="3" pm="."><plain>Under <z:chebi fb="0" ids="5615">fluothane</z:chebi> anaesthesia, rats were subjected to 10 min four vessel occlusion and gerbils to either (i) 5 or (ii) 10 min bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>3 </plain></SENT>
<SENT sid="5" pm="."><plain>Rats were dosed parenterally solely post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> (reperfusion) in a series of five studies covering a range of intra-arterial/intraperitoneal (i.a./i.p.) combination doses from 2/10, 5/20, 20/100, 50/200 and 100/500 micrograms kg-1, where the initial loading dose was injected i.a. at 5 min </plain></SENT>
<SENT sid="6" pm="."><plain>An i.p. dose was given at 15 min and repeated twice daily </plain></SENT>
<SENT sid="7" pm="."><plain>In a sixth study, treatment at 50/200 micrograms kg-1 was deferred for 1 h </plain></SENT>
<SENT sid="8" pm="."><plain>4 </plain></SENT>
<SENT sid="9" pm="."><plain>Gerbils were treated (i) 15 min pre-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> with either (a) 250, (b) 500 micrograms kg-1 i.p., or (c) 5 mg kg-1 by gavage (p.o.) for 3 days then at 1 h pre-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Animals treated as (ii) received 500 micrograms kg-1 i.p </plain></SENT>
<SENT sid="11" pm="."><plain>15 min pre-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>The above doses were repeated twice daily for 3 days post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> for the respective groups </plain></SENT>
<SENT sid="13" pm="."><plain>5 </plain></SENT>
<SENT sid="14" pm="."><plain>In rats, the protective effect of lifarizine was regionally and cumulatively assessed in six brain regions (anterior and posterior neocortex, hippocampal CA1 subfield, thalamus, striatum, cerebellar Purkinje cells-brain stem) at each dose level </plain></SENT>
<SENT sid="15" pm="."><plain>Cumulative (total) means +/-s.e.mean neurohistopathological scores(0-4) of 1.16+/-0.09 (n=5), 1.02+/-0.10 (n=5), 0.93+/-0.06 (n=6), 0.79+/-0.09 (n=9) and 0.45+/-0.16(n = 7), respectively, were obtained for the above treatment groups compared to the control (2.01 +/- 0.17,n = 16) group (P&lt;0.0035) </plain></SENT>
<SENT sid="16" pm="."><plain>The score for the 1 h deferred treatment group was also significant at 0.77 +/- 0.10, n =5 (P&lt; 0.0035) </plain></SENT>
<SENT sid="17" pm="."><plain>The <z:mpath ids='MPATH_458'>normal</z:mpath> group without <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> showed a score of 0.52 +/- 0.09 (n = 6).6 </plain></SENT>
<SENT sid="18" pm="."><plain>In gerbils, (i) percentage delayed neuronal <z:hpo ids='HP_0011420'>death</z:hpo> (DND) of hippocampal pyramidal cells in the CA1subfield was prevented at 250 (a) and 500 microg kg-' i.p </plain></SENT>
<SENT sid="19" pm="."><plain>(b) (27.2+/- 14.6, n=6 and 26.9+/- 10.4%, n= 10 respectively, P&lt;0.02) compared to controls (78.3+/-8.5%, n= 12) and by 5 mg kg-1 p.o </plain></SENT>
<SENT sid="20" pm="."><plain>(c) (2.9+/-0.8%,n =l1, P &lt;0.002) </plain></SENT>
<SENT sid="21" pm="."><plain>Mean +/- s.e.mean total brain scores (0-4) for each of 4 different features denoting cerebral '<z:hpo ids='HP_0000969'>oedema</z:hpo>' were lower for <z:mpath ids='MPATH_458'>normal</z:mpath> brains (1.60 +/-0.34, n =6) and reduced in animals dosed at 250(a) (3.00+/-0.79, n=6) and 500 microg kg-1 i.p </plain></SENT>
<SENT sid="22" pm="."><plain>(b) (3.75 0.36, n= 10) compared to controls (6.58+/-1.00,n = 12) (P&lt; 0.02 -0.03) </plain></SENT>
<SENT sid="23" pm="."><plain>There was a linear relationship (r = 0.97) between the '<z:hpo ids='HP_0000969'>oedema</z:hpo>' scores and percentage CA1 DND </plain></SENT>
<SENT sid="24" pm="."><plain>Percentage CA1 DND in response to 10 min <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> (ii) was reduced(53.0+/-21.0%, n=6, P&lt;0.05) compared to controls (100.0+/-0.0%, n=7).7 The significant neuroprotection shown by lifarizine in rodents substantiates findings in other species.These observations, together with its effect on ion channels and efficacy at extremely low doses offers novelty and suggests a broad spectrum of activity in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
</text></document>